The Hidden Cost of Heart Failure

What "Catastrophic" Actually Means

The World Health Organization defines catastrophic health expenditure as spending more than 40% of your household income (after basic needs) on healthcare.

Let's put real numbers to that:

Maria is 67. Heart failure with reduced ejection fraction. Lives on Social Security: $1,800/month. Rent: $900. Food, utilities: $500. That leaves $400/month.

Her medications: $280/month after insurance. Cardiology visits (copays): $60/month average. ER visit last month (unexpected): $350.
This month, she's $290 over budget. She skips two medications. Eats less. Borrows from her daughter.
Next month, she's admitted for decompensation. Hospital bill: $2,800 after insurance.
She stops taking all her medications. Two weeks later, she's back in the ER.

This isn't a failure of clinical care. It's a failure of economic reality colliding with disease management.

The Math That Doesn't Add Up

Medications and health insurance premiums represent the largest categories of out-of-pocket expenses for heart failure families. AHA Journals

Let that sink in. The two things patients absolutely cannot skip—medications and insurance—are the things bankrupting them.

Here's the cruel irony: Heart failure requires expensive adherence.
Not just one medication. A cocktail: ACE inhibitor, beta-blocker, diuretic, aldosterone antagonist. Maybe SGLT2 inhibitor if insurance covers it. Maybe ARNI if they can afford it.
Each one costs money. Each copay adds up. Miss one, and your heart starts failing harder. End up in the hospital, and the bills multiply.
Low-income families had 14-fold greater risk-adjusted odds of catastrophic financial burden compared to middle/high-income families. AHA Journals

It's not that low-income families are less compliant. It's that the cost of compliance is impossible.

The Domino Effect

Here's what happens when a family can't afford heart failure care:

• Step 1: Medication non-adherence. Not because they don't understand. Because they can't afford it.

• Step 2: Symptoms worsen. Fluid retention. Shortness of breath. Fatigue. But going to the doctor costs money, so they wait.

• Step 3: Emergency admission. They collapse. ER visit. Hospital stay. Thousands of dollars.

• Step 4: Medical debt. Can't pay the bill. Goes to collections. Credit destroyed. Can't get a loan for a car. Can't move to cheaper housing because credit check fails.

• Step 5: Lost income. Too sick to work. Or working reduced hours. Income drops. Can't afford medications. Return to Step 1.

This isn't a cycle. It's a death spiral.

And the hospital sees it happening in real-time—but the system isn't designed to intervene at the financial level, only the clinical one.

Why Remote Monitoring Should Matter Most Here

Heart failure costs in the US are projected to reach $70 billion by 2030. The Intake
But that's system-level spending. What about family-level?

Here's the math that should guide every heart failure intervention:

One prevented hospitalization = $8,000-15,000 saved (system cost) One prevented hospitalization = potentially avoiding financial catastrophe (family cost)

Remote monitoring isn't just about clinical outcomes. It's about preventing the cascading financial devastation that comes with repeated hospitalizations.

At Sensocor ML, we think about this constantly.

If we can detect hemodynamic deterioration before it becomes symptomatic, we've prevented:

• The ER visit

• The hospital stay

• The lost wages from missed work

• The transportation costs to/from hospital

• The childcare or elder care costs during admission

• The psychological toll of another crisis

That's not just better medicine. That's economic intervention.

The Equity Problem No One's Solving

Overall, 14% of families with heart failure experienced high financial burden, and 5% experienced catastrophic burden. AHA Journals

But when you break it down by income:

• Middle/high-income families: Manageable burden

• Low-income families: 24% high burden, 10% catastrophic burden AHA Journals

Same disease. Different economic realities. Completely different outcomes.

Here's what this means in practice: The patients who would benefit most from remote monitoring—the ones at highest risk of financial catastrophe from hospitalization—are the ones least likely to have access to it.
Insurance may not cover it. The device may require smartphone ownership and reliable internet. The clinic may not offer it to Medicaid patients.
We've built a system where the most expensive intervention (repeated hospitalizations) is universally covered, but the preventive intervention (remote monitoring) is reserved for those with good insurance.

That's not just inefficient. It's cruel.

What Actually Needs to Change

1. Coverage parity. Remote monitoring for heart failure should be covered the same way hospitalizations are—universally, with minimal out-of-pocket cost. If preventing a $15,000 admission costs $50/month in monitoring, that's not an expense. That's an investment.
2. Medication affordability. We can have the best monitoring system in the world, but if patients can't afford their medications, they'll still end up hospitalized. Drug pricing reform isn't optional—it's essential to heart failure management.
3. Financial toxicity screening. Every heart failure clinic should screen for financial burden the same way they screen for depression. If a patient is choosing between meds and rent, that's a clinical risk factor that needs intervention.
4. Technology designed for economic realities. Remote monitoring systems need to work for patients without smartphones, without reliable internet, without health literacy. If your technology requires resources low-income patients don't have, you're not solving the problem—you're widening the gap.

The Bottom Line

The clinical community has spent decades optimizing heart failure treatment. Guideline-directed medical therapy. Device therapy. Multidisciplinary care teams.

And it works—if you can afford it.

For the millions of families facing financial toxicity from heart failure, the question isn't "What's the best medication?" It's "Can I afford this medication and still eat?"
Until we address that question, our clinical innovations will continue to benefit those who can afford them while others quietly drown in medical debt.

Does your heart failure program measure financial burden the same way it measures ejection fraction?

Because if it doesn't, you're only treating half the problem.

Sources:

• Abdalla M, et al. (2021). Out-of-Pocket Annual Health Expenditures and Financial Toxicity From Healthcare Costs in Patients With Heart Failure in the United States. Journal of the American Heart Association. DOI: 10.1161/JAHA.121.022164

• Chen W, et al. (2024). The Economics of Heart Failure Care. Progress in Cardiovascular Diseases. DOI: 10.1016/j.pcad.2024.01.010

• Darvish M, et al. (2025). Heart Failure: Assessment of the Global Economic Burden. European Heart Journal.